Evidence map›Paper›PMID 37775665›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2024

Formulation of Chitosan-Zein Nano-in-Microparticles for Oral DNA Delivery.

Kari Heck, Eric Farris, Angela K Pannier

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kari HeckDepartment of Biological Systems Engineering, University of Nebraska-Lincoln, Lincoln, NE, USA.
Eric FarrisAdjuvance Technologies Inc., Lincoln, NE, USA.
Angela K PannierDepartment of Biological Systems Engineering, University of Nebraska-Lincoln, Lincoln, NE, USA. apannier2@unl.edu.

Funding

UNMC Structural Biology CoreP20GM103427 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI PAUL L SORGEN · 2012 to 2026
$59.2M
Using Cell Priming and Telecommunications Modeling to Enhance Gene Delivery for Stem Cell TherapiesDP2EB025760 · NIBIB · UNIVERSITY OF NEBRASKA LINCOLN · PI PANNIER, ANGELA K · 2017 to 2022
$2.8M
Molecular Mechanisms of DiseaseT32GM107001 · NIGMS · UNIVERSITY OF NEBRASKA LINCOLN · PI BECKER, DONALD F, BLACK, PAUL N. · 2015 to 2019
$1.0M
NIBIB NIH HHS DP2 EB025760NIGMS NIH HHS P20 GM103427NIGMS NIH HHS T32 GM107001
6 · The paper itself

Abstract

Gene delivery via the oral route offers a promising strategy for improving DNA vaccination and gene-based therapy outcomes. The noninvasive nature of oral delivery lends to ease of dosing, which can facilitate convenience and patient compliance. Moreover, oral administration allows for both local and systemic production of therapeutic genes or, in the case of DNA vaccination, mucosal and systemic immunity. Here, we describe the methods to produce a dual biomaterial, oral DNA delivery system composed of chitosan (CS) and zein (ZN). In this system, CS serves to encapsulate and deliver DNA cargo to intestinal cells in the form of CS-DNA nanoparticles (CS-DNA NPs), while ZN is used to form a protective matrix around the CS-DNA NPs that prevent degradation during gastric transit but then degrades to release the CS-DNA NPs for transfection upon entry into the intestines. These particles have demonstrated the ability to effectively protect cargo DNA from simulated gastric degradation in vitro and mediate transgene production in vivo, making them an effective oral gene delivery system.

Indexed as

ChitosanNanoparticlesZeinAdministration, OralDNADrug CarriersGene Transfer TechniquesHumansTransfectionChitosanDNADrug CarriersZeinChitosanGene deliveryGene therapyNano-in-microparticlesOral deliveryZein

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.